Bipolar disorder (manic depression) is a chronic mental health condition characterized by extreme mood swings, including emotional highs (mania) and lows (depression). As per Yunxi Zhong et al., 2024, globally, the incidence of bipolar disorder among adolescents and young adults increased from 79.21 per 100,000 population. According to the bipolar disorder (manic depression) pipeline analysis by Expert Market Research, the market is witnessing a growing focus on targeted bipolar disorder therapeutics. With increasing awareness, improved diagnostics, and research advancements, the treatment landscape is projected to witness significant growth in the coming years.
Major companies involved in the bipolar disorder (manic depression) pipeline analysis include BioXcel Therapeutics Inc., Autobahn Therapeutics, Inc., and others.
Leading drugs currently in the pipeline include BXCL501, ABX-002, BXCL501, and others.
The pipeline for bipolar disorder is advancing with growing focus on novel mood stabilizers, glutamate modulators, and precision psychiatry approaches, driving targeted treatment development and enhanced clinical trial activity.
The Bipolar Disorder (Manic Depression) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bipolar disorder (manic depression) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bipolar disorder (manic depression). The bipolar disorder (manic depression) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The bipolar disorder (manic depression) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bipolar disorder (manic depression) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bipolar disorder (manic depression).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Bipolar disorder, also known as manic depression, is a chronic mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). It occurs due to complex interactions among genetic, biochemical, and environmental factors, which disrupt normal brain function and emotional regulation, often impairing daily activities and personal relationships.
Bipolar disorder is typically treated with mood stabilizers, antipsychotics, and antidepressants, alongside psychotherapy. The treatment aims to manage episodes, reduce symptoms, and prevent relapse. Early diagnosis and ongoing medical supervision significantly improve long-term outcomes and patient quality of life. In April 2024, the U.S. Food and Drug Administration approved Fanapt (iloperidone) for the acute treatment of manic or mixed episodes linked to bipolar I disorder. The approval followed successful Phase 3 trial results showing significant symptom reduction and improved patient outcomes.
According to Yunxi Zhong et al. (2024), the global incidence of bipolar disorder among adolescents and young adults has increased to 79.21 per 100,000 population. As per the University of St. Augustine for Health Sciences, the National Institutes of Health (NIH) reports that 2.8% of adults in the United States are affected by bipolar disorder. Additionally, around 0.5% of India’s population is impacted. The growing prevalence highlights a rising need for innovative therapies and expanded drug development efforts.
This section of the report covers the analysis of bipolar disorder (manic depression) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The bipolar disorder (manic depression) pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II at 33%, covers a major share of the total bipolar disorder (manic depression) clinical trials. It is followed by phase III at 28%, and phase IV at 20%. This balanced pipeline distribution reflects strong clinical advancement, indicating significant growth potential and continuous innovation in the bipolar disorder (manic depression) treatment market.
The drug molecule categories covered under the bipolar disorder (manic depression) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The bipolar disorder (manic depression) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bipolar disorder (manic depression). Next-generation lithium-based therapies are gaining attention as safer alternatives for treating bipolar disorder. For instance, AL001, developed by Alzamend Neuro Inc., utilizes a patented ionic cocrystal technology combining lithium, proline, and salicylate to target lithium delivery specifically to the brain. This approach aims to minimize systemic toxicity and reduce the need for therapeutic drug monitoring, thereby enhancing treatment safety and effectiveness for patients with bipolar disorder type 1.
The EMR report for the bipolar disorder (manic depression) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bipolar disorder (manic depression) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bipolar disorder (manic depression) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bipolar disorder (manic depression). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bipolar disorder (manic depression) drug candidates.
BXCL501, a proprietary orally dissolving film formulation of dexmedetomidine, is being developed by BioXcel Therapeutics. It is currently undergoing Phase III trials to assess its safety and efficacy for at-home treatment of agitation associated with bipolar I or II disorder and schizophrenia. BXCL501 is a selective alpha-2 adrenergic receptor agonist, designed to calm without heavy sedation. This study is evaluating a 120 mcg dose used as needed at home, aiming to offer patients rapid, discreet relief during agitation episodes outside clinical settings.
ABX-002 is an orally administered, potent thyroid hormone beta receptor (TRβ) agonist being developed by Autobahn Therapeutics. It targets brain bioenergetics to address depressive symptoms in bipolar disorder. By selectively activating TRβ in the central nervous system, ABX-002 aims on enhancing antidepressant effects without the systemic side effects linked to traditional thyroid hormone therapies like T3. The ongoing Phase 2 trial is evaluating its impact as an adjunctive treatment in adults with bipolar depression, focusing on changes in brain chemistry related to mood regulation.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bipolar Disorder (Manic Depression) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bipolar disorder (manic depression). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bipolar disorder (manic depression) collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share